Table 2.

Treatment Administration.

	This Cohort (n=46)
Study treatment
Time of lenvatinib (months)
Mean ± SD	11.6 ± 7.9
Median (IQR)	10.4 (6.7-15.0)
Cycles of FOLFOX-HAIC, median (IQR)	3.0 (2.0-4.0)
Cycles of PD1 inhibitor, median (IQR)	8.0 (5.3-12.0)
PD1 inhibitors
Sintilimab	18
Toripalimab	11
Camrelizumab	10
Tislelizumab	5
Pembrolizumab	2
Post-study treatment
Resection	3
Chemotherapy	18
TACE	8
Radiotherapy	5
Other TKIs	14
Other PD1 inhibitors	13